Dr Haumschild leads a discussion surrounding the latest advancements in treatment algorithms for myelodysplastic syndrome. The discussion centered on diverse treatment strategies for myelodysplastic ...
Recent advances in defining low- and intermediate-risk myelodysplastic syndromes (MDSs) have emphasized the critical role of molecular characterization using next-generation sequencing (NGS).
Hypomethylating agents are standard in MDS treatment, with new drugs like Rytelo enhancing anemia management. Targeted therapies for IDH1/IDH2 mutations offer promising options, though challenges in ...
The expert panel looks to future treatment management for patients with myelodysplastic syndrome. Ryan Haumschild, PharmD, MS, MBA: I want to think about the future. How is the future changing? Dr ...
According to results from the IMerge trial, 2 39.8% of patients treated with imetelstat achieved 8 weeks of transfusion independence compared with 15.0% of patients treated with placebo. Respondents ...
Please provide your email address to receive an email when new articles are posted on . Most patients with newly diagnosed high-risk myelodysplastic syndrome do not receive guideline-recommended ...
Dr. Shah was compensated by BMS for his participation. Photo Credit: Shutterstock As you age, feeling tired or short of breath may be dismissed as a part of getting older, but it’s important to talk ...
FOSTER CITY, Calif.--(BUSINESS WIRE)--Geron Corporation (Nasdaq: GERN), a commercial-stage biopharmaceutical company aiming to change lives by changing the course of blood cancer, today announced that ...
Combine these seemingly contradictory facts with a difficult-to-pronounce name and a prognostic schema (the International Prognostic Scoring System [IPSS]) that has been co-opted as a default staging ...
FOSTER CITY, Calif.--(BUSINESS WIRE)--Geron Corporation (Nasdaq: GERN), a commercial-stage biopharmaceutical company aiming to change lives by changing the course of blood cancer, today announced that ...
Hosted on MSN
Many patients with high-risk myelodysplastic syndromes do not receive guideline-recommended treatment
Most patients with high-risk myelodysplastic syndromes (MDS) do not receive guideline-recommended treatment with hypomethylating agents (HMAs), according to results published inBlood Neoplasia. The ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results